AUTHORS
Douglas Tremblay, MD, Ann Mercurio, MD2, Kimberly Basalyga, MD3, Brandon James Aubrey, MBBS PhD FRACP FRCPA4, Robert P Hasserjian, MD5, Christian Salib, MD6, Sanam Loghavi, MD7, Guillermo Garcia-Manero, MD8, Breanna Chandler, M.D.9, Jessica Maria Stempel, MD, MHS10, Gillian Sanchez11, Zena Komrokji12, Elizabeth Rinker13, Daniel Nathan, MD14, Hannah Levavi, MD15, Marina Kremyanskaya, MD, PhD16, John O. Mascarenhas, MD17, Carlos Bueso-Ramos, M.D., Ph.D.18, Shivani Handa, MD19, Andrew Srisuwananukorn, MD20, Christina Kim21, David Swoboda, MD22, Theodore Paul Braun, MD PhD23, Anand Ashwin Patel, MD24, Ami B. Patel, MD25, Alexander Coltoff, MD26, Aditi Shastri, MD27, Anthony Michael Hunter, MD28, Abhay Singh, MD, MPH29, Akriti G Jain, MD, FACP30, Andrew M Brunner, MD31, Eric Padron, MD32, Guillermo Montalban-Bravo, MD33
AFFILIATIONS
1 Icahn School of Medicine at Mount Sinai, New York, New York, United States
2 Icahn School of Medicine at Mount Sinai, New York, New York, United States
3 Montefiore Medical Center, Bronx, New York, United States
4 Mass General Brigham Cancer Institute, Boston, Massachusetts, United States
5 Mass General Brigham Cancer Institute, Boston, Massachusetts, United States
6 Icahn School of Medicine at Mount Sinai, New York, New York, United States
7 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
8 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
9 University of Chicago, Chicago, Illinois, United States
10 Oregon Health and Science University, Portland, Illinois, United States
11 Icahn School of Medicine at Mount Sinai, New York, New York, United States
12 Moffitt Cancer Center, Tampa, United States
13 Medical University of South Carolina, Charleston, South Carolina, United States
14 Icahn School of Medicine at Mount Sinai, New York, New York, United States
15 Icahn School of Medicine at Mount Sinai, New York, New York, United States
16 Icahn School of Medicine at Mount Sinai, New York, New York, United States
17 Icahn School of Medicine at Mount Sinai, New York, New York, United States
18 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
19 Ohio State University, Columbus, Ohio, United States
20 Ohio State University, Columbus, Ohio, United States
21 Tampa General Hospital Cancer Institute, Tampa, Florida, United States
22 Tampa General Hospital Cancer Institute, Tampa, Florida, United States
23 Oregon Health and Science University, Portland, Illinois, United States
24 University of Chicago, Chicago, Illinois, United States
25 University of Utah, Salt Lake City, Utah, United States
26 Medical University of South Carolina, Charleston, South Carolina, United States
27 Montefiore Medical Center, Bronx, New York, United States
28 Winship Cancer Institute of Emory University, Atlanta, Georgia
29 Cleveland Clinic, Cleveland, Ohio, United States
30 Cleveland Clinic, Cleveland, Ohio, United States
31 Mass General Brigham Cancer Institute, Boston, Massachusetts, United States
32 Moffitt Cancer Center, Tampa, United States
33 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
ABSTRACT
Background
Atypical chronic myeloid leukemia / myelodysplastic/myeloproliferative neoplasm with neutrophilia (aCML) is a rare MDS/MPN entity with a poor prognosis and high risk of transformation to acute myeloid leukemia (AML). Prior single-institution series have characterized its mutational landscape and clinical outcomes, but small sample sizes have limited generalizability of prognostic estimates and the optimal treatment approach remains unclear. A large multicenter cohort is needed to improve risk stratification and define effective therapeutic strategies.
Methods
We retrospectively identified WHO/ICC-defined aCML cases evaluated across 13 institutions. Complete response (CR) and overall response rates (ORR) were assessed per MDS/MPN International Working Group (IWG) criteria (Savona 2015). Median overall survival (mOS) and AML-free survival (AMLFS) were estimated by Kaplan-Meier methodology. A prognostic scoring system was developed using multivariable Cox regression with integer weights derived from model coefficients.
Results
We identified 184 aCML patients with a median age of 72 years (interquartile range 65-77), 68% were male. At baseline, median WBC was 42.5x109/L with median 20% circulating neutrophil precursors. Peripheral blasts ≥1% were present in 45% of cases. Median hemoglobin (hgb) and platelet count (plt) were 9.7 g/dL and 129x109/L, respectively with 26.1% of patients being red blood cell transfusion-dependent at diagnosis. Bone marrow (BM) blasts were ≥5% in 19% of patients. Palpable splenomegaly was present in 42% of patients and non-hepatosplenic extramedullary disease was identified in 8 (4%) patients.
Cytogenetics were abnormal in 37% and complex in 9.4% of patients with available data. Molecular data were available at diagnosis in 165 (90%) of patients and notable for: ASXL1 (68%), SRSF2 (49%), SETBP1 (40%), TET2 (34%), EZH2 (17%), GATA2 (14%), NRAS (13%), U2AF1 (12%), RUNX1 (12%), CBL (10%), and CSF3R (8%, mostly T618I). The most common co-mutational patterns included ASXL1-SRSF2 (38%), ASXL1-SETBP1 (30%) and SETBP1-SRSF2 (30%). SRSF2 (median variant allele frequency [VAF] 46.8%), TET2 (46.8%), and SETBP1 (45.1%) demonstrated high VAF with majority of mutations (79%) exceeding the 40% threshold consistent with clonal dominance, supporting their role as founder mutations. In contrast, NRAS (median VAF 39.9%) and CBL (35.9%) showed wider VAF distributions consistent with subclonal acquisition.
Frontline treatments included hypomethylating agents (HMA) (alone, N=45; or in combination, N=4), hydroxyurea (N=47), ruxolitinib (N=24) and cytotoxic chemotherapy (N=20), with CR/ORR rates for each intervention were 6%/29%, 0%/9%, 0%/17%, and 10%/50%, respectively. A total of 83 patients (45%) received HMA (alone n=69, combination n=14) at some point in their treatment, with CR/ORR rates of 5%/22%. Combination partners for HMA included venetoclax (n=6), FLT3 inhibitors (n=3), investigational drugs (n=2) and unknown regimens (n=3). A total of 45 patients (24%) underwent transplant (HSCT). When regarded as a time-dependent covariate, HSCT was associated with a significant improvement in survival (HR 0.28, 95%CI 0.15-0.52).
After a median follow-up of 41.9 months (mos), 25 patients (14%) transformed to AML with a median AMLFS of 20 mos (95%CI 17.1-28).
Overall, the mOS was 24.2 mos (95%CI 17.7-29). Multivariable analysis identified the following prognostic factors in the subset with available NGS: plt <100 x109/L (HR 1.84), BM blasts ≥5% (HR 1.48), hgb <10 g/dL (HR 1.33) and RUNX1 mutation (HR 1.39). Using this we developed the aCML-specific Prognostic Scoring System (APSS) (plt <100x109/L, 2 points; BM blasts ≥5%, 1 point; hgb <10 g/dL, 1 point; RUNX1, 1 point) that stratified patients into low- (0 points, mOS 39.9 mo), intermediate- (1-2 points, 20.1 mo) or high-risk (3+ points, 12.3 mo) groups. Stratification was significant for OS (p<0.001) and AMLFS (p<0.001).
Conclusions
In the largest clinically annotated cohort of patients with aCML to date, we note poor response rates to conventional frontline therapies (CR ≤10% across all regimens) and a significant survival benefit with HSCT. Further, we developed a novel prognostic scoring system that effectively stratified patients into low-, intermediate-, and high-risk groups based on plt count, BM blast percentage, hgb, and RUNX1 mutation status to serve as a tool for informing counseling and identifying patients who may benefit from early transplantation.
DISCLOSURES
Douglas Tremblay, MD: Cogent - Research Funding; Oryzon - Research Funding; Sobi - Research Funding; Geron - Research Funding; Blueprint - Research Funding; AbbVie - Consultancy (Includes expert testimony); Sobi - Consultancy (Includes expert testimony); Cogent - Consultancy (Includes expert testimony); Takeda - Consultancy (Includes expert testimony); Pharmaessentia - Consultancy (Includes expert testimony); Incyte - Consultancy (Includes expert testimony); Ipsen - Consultancy (Includes expert testimony); Geron - Consultancy (Includes expert testimony)